Jefferies upgraded Glaukos from Hold to Buy and set a new price target of $125.00 from $84.00 previously
Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/1/2025 | $86.00 | Overweight → Equal Weight | Wells Fargo |
| 2/19/2025 | $140.00 → $200.00 | Neutral → Outperform | Mizuho |
| 12/11/2024 | $132.00 → $162.00 | Neutral → Buy | Citigroup |
| 12/6/2024 | $182.00 | Buy | UBS |
| 12/2/2024 | $120.00 | Equal-Weight → Underweight | Morgan Stanley |
| 7/10/2024 | $132.00 | Buy → Neutral | Citigroup |
| 5/6/2024 | $84.00 → $125.00 | Hold → Buy | Jefferies |
| 12/21/2023 | $66.00 → $91.00 | Neutral → Overweight | JP Morgan |
Wells Fargo downgraded Glaukos from Overweight to Equal Weight and set a new price target of $86.00
Mizuho upgraded Glaukos from Neutral to Outperform and set a new price target of $200.00 from $140.00 previously
Citigroup upgraded Glaukos from Neutral to Buy and set a new price target of $162.00 from $132.00 previously
Regulatory Clearances Support Glaukos' Plans to Advance and Accelerate its Interventional Glaucoma Initiatives Globally Marks the Company's First Regulatory Clearances Under the New EU Regulatory Framework Glaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced it has received European Union (EU) Medical Device Regulation (MDR) certification for iStent infinite®, along with several of its other leading micro-invasive glaucoma surgery (MIGS) technologies, including iStent inject® W. Glaukos' iStent® trabecular micro-bypass stenting platfor
NEW YORK, June 25, 2025 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins. Kristen Scholer delivers the pre-market update on June 25th Equities are little changed Wednesday morning after jumping by more than 1% on Tuesday. The DOW gained over 500 points while the S&P 500 sits just shy of a record high.Driving those gains were easing tensions in the Middle East, resulting in crude oil prices falling by approximately 5% during Tuesday's session. President Trump announced a ceasefire agreement on Monday night.Fed
Glaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced it will celebrate the 10th anniversary of its Initial Public Offering (IPO) listing on the New York Stock Exchange (NYSE) by ringing The Closing Bell at 4:00 p.m. ET today, Wednesday, June 25, 2025. "Ringing the NYSE closing bell today is a proud and humbling moment for our company, commemorating ten years since our IPO and celebrating the tremendous progress we've made in advancing our mission to transform vision therapies for the benefit of patients suffering from chronic eye disease
Submission status for GLAUKOS CORP's drug IDOSE TR (ORIG-1) with active ingredient TRAVOPROST has changed to 'Approval' on 12/13/2023. Application Category: NDA, Application Number: 218010, Application Classification: Type 3 - New Dosage Form
Submission status for GLAUKOS CORP's drug TRAVOPROST (ORIG-1) with active ingredient TRAVOPROST has changed to 'Approval' on 12/13/2023. Application Category: NDA, Application Number: 218010, Application Classification: Type 3 - New Dosage Form
8-K - GLAUKOS Corp (0001192448) (Filer)
SD - GLAUKOS Corp (0001192448) (Filer)
8-K - GLAUKOS Corp (0001192448) (Filer)
SC 13G/A - GLAUKOS Corp (0001192448) (Subject)
SC 13G/A - GLAUKOS Corp (0001192448) (Subject)
SC 13G/A - GLAUKOS Corp (0001192448) (Subject)
4 - GLAUKOS Corp (0001192448) (Issuer)
4 - GLAUKOS Corp (0001192448) (Issuer)
4 - GLAUKOS Corp (0001192448) (Issuer)
NEW YORK, Jan. 4, 2023 /PRNewswire/ -- OnCusp Therapeutics, a global biotechnology company with deep translational and clinical development expertise in oncology therapeutics, today announced the appointment of serial entrepreneur Robert Forrester and venture capitalist Chau Khuong as independent board directors. "We are delighted to have Robert and Chau, two seasoned leaders with a wealth of insights and expertise, to join OnCusp's Board. Both are highly regarded and deeply connected in the biotech and investment community," said Dr. Bing Yuan, Chairman and CEO of OnCusp. "Each of these individuals brings unique skill sets to our Board and will be instrumental to advancing OnCusp through se
Glaukos Corporation (NYSE:GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that William J. Link, Ph.D., will be retiring as Chairman of the Board, effective December 31, 2021. Dr. Link joined Glaukos' Board and has served as Chairman since June 2001. In connection with Dr. Link's retirement, the Board has appointed Thomas W. Burns, Glaukos' President and Chief Executive Officer and a director on the Board since 2002, to serve as the company's Chairman of the Board, effective upon Dr. Link's retirement on December 31, 2021. Mr. Burns will continue to serve as th
SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced the appointment of Denice Torres and Dr. Leana Wen to its Board of Directors, effective today. With the addition of these two directors, Glaukos’ Board of Directors will be comprised of nine directors, eight of whom are independent. “We are delighted and honored to welcome these highly accomplished professionals to the Glaukos Board. Each of these extraordinary women brings a wealth of relevant experience, perspective, leadership and wis
Glaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the first quarter ended March 31, 2025. Key highlights include: Record net sales of $106.7 million in Q1 2025 increased 25% year-over-year on a reported basis and 26% year-over-year on a constant currency basis. Glaucoma record net sales of $88.1 million in Q1 2025 increased 31% year-over-year. U.S. Glaucoma record net sales of $59.1 million in Q1 2025 increased 41% year-over-year. Gross margin of approximately 77% and non-GAAP gross margin of approximately
Conference Call and Webcast Scheduled for 1:30 p.m. PT Glaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release first quarter 2025 financial results after the market close on Wednesday, April 30, 2025. The company's management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PT (4:30 p.m. ET) on April 30, 2025. A link to the live webcast will be available on the company's website at http://investors.glaukos.com. To participate in the conference call, please dial 800-715-9871 (U.S.) or 646-307-1963 (Int
Glaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the fourth quarter and full year ended December 31, 2024. Key highlights include: Record net sales of $105.5 million in Q4 2024 increased 28% year-over-year. Glaucoma record net sales of $84.1 million in Q4 2024 increased 39% year-over-year. Gross margin of approximately 73% and non-GAAP gross margin of approximately 82% in Q4 2024. Net sales of $383.5 million in FY 2024 increased 22% year-over-year. Introduced 2025 net sales guidance of $475 million to $4